Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Sell
49
ERFSF Quote, Financials, Valuation and Earnings
Last price:
$53.16
Seasonality move
:
5.16%
Day range:
$51.75 - $55.85
52-week range:
$44.61 - $68.45
Dividend yield:
1.01%
P/E ratio:
23.73x
P/S ratio:
1.39x
P/B ratio:
1.74x
Volume:
3.2K
Avg. volume:
2.2K
1-year change:
-17.42%
Market cap:
$9.6B
Revenue:
$7.5B
EPS (TTM):
$2.24
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Eurofins Scientific SE has -- downside to fair value with a price target of -- per share.
ERFSF vs. S&P 500
-
Over the past 5 trading days, Eurofins Scientific SE has underperformed the S&P 500 by -6.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Eurofins Scientific SE does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eurofins Scientific SE has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Eurofins Scientific SE reported revenues of --.
Earnings Growth
-
Eurofins Scientific SE has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Eurofins Scientific SE reported earnings per share of --.
Enterprise value:
12.2B
EV / Invested capital:
--
Price / LTM sales:
1.39x
EV / EBIT:
16.11x
EV / Revenue:
1.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
8.14x
Gross Profit (TTM):
--
Return On Assets:
3.74%
Net Income Margin (TTM):
5.85%
Return On Equity:
7.71%
Return On Invested Capital:
4.85%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $253M | $327.5M | |
| Gross Profit | -- | -- | -- | $160.2M | $212.1M | |
| Operating Income | -- | -- | -- | $23.1M | $49M | |
| EBITDA | -- | -- | -- | $37.4M | $59.8M | |
| Diluted EPS | -- | -- | -- | $0.01 | $0.10 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.1B | $2.6B | $2.5B | $3.4B | $2.6B | |
| Total Assets | $10.5B | $10.6B | $10.8B | $12B | $11.3B | |
| Current Liabilities | $2.1B | $2.1B | $1.9B | $2.3B | $2.2B | |
| Total Liabilities | $6B | $5.3B | $5.6B | $6.4B | $5.7B | |
| Total Equity | $4.6B | $5.3B | $5.2B | $5.7B | $5.6B | |
| Total Debt | $3.2B | $2.5B | $3B | $3.7B | $3.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $63.2M | $72.8M | |
| Cash From Investing | -- | -- | -- | -$19.9M | -$41.1M | |
| Cash From Financing | -- | -- | -- | -$12.9M | -$7.5M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
ERFSF
Sector
Market Cap
$9.6B
$33.9M
Price % of 52-Week High
77.67%
41.2%
Dividend Yield
1.01%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-17.42%
-46.15%
Beta (5-Year)
0.731
0.743
Dividend yield:
1.01%
Annualized payout:
$0.54
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$52.91
200-day SMA
Sell
Level
$53.61
Bollinger Bands (100)
Buy
Level
49.02 - 54.18
Chaikin Money Flow
Buy
Level
3.2K
20-day SMA
Sell
Level
$54.04
Relative Strength Index (RSI14)
Sell
Level
48.83
ADX Line
Sell
Level
12.56
Williams %R
Neutral
Level
-45.3412
50-day SMA
Sell
Level
$53.43
MACD (12, 26)
Buy
Level
11.03
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-24K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2967)
Buy
CA Score
(Annual)
Level (-0.0191)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.8823)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eurofins, headquartered in Luxembourg, has three main business lines: food and environment testing, services to pharmaceutical and biotechnology companies, and clinical diagnostics. Through its subsidiaries, Eurofins provides various analytical testing and laboratory services on a global scale, and the company offers testing options for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products. The company also has a growing clinical diagnostics unit, with specialties in infectious diseases, prenatal screening, and organ transfer. Eurofins operates over 900 laboratories in 54 countries.
Stock Forecast FAQ
In the current month, ERFSF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ERFSF average analyst price target in the past 3 months is --.
-
Where Will Eurofins Scientific SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eurofins Scientific SE share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Eurofins Scientific SE?
Analysts are divided on their view about Eurofins Scientific SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eurofins Scientific SE is a Sell and believe this share price will rise from its current level to --.
-
What Is Eurofins Scientific SE's Price Target?
The price target for Eurofins Scientific SE over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ERFSF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eurofins Scientific SE is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ERFSF?
You can purchase shares of Eurofins Scientific SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eurofins Scientific SE shares.
-
What Is The Eurofins Scientific SE Share Price Today?
Eurofins Scientific SE was last trading at $53.16 per share. This represents the most recent stock quote for Eurofins Scientific SE. Yesterday, Eurofins Scientific SE closed at $53.16 per share.
-
How To Buy Eurofins Scientific SE Stock Online?
In order to purchase Eurofins Scientific SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
